These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 31739193)
21. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis. Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436 [TBL] [Abstract][Full Text] [Related]
22. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection. Hu S; Chen H; Ma J; Chen Q; Deng H; Gong F; Huang H; Shi C J Appl Microbiol; 2013 Nov; 115(5):1203-11. PubMed ID: 23902541 [TBL] [Abstract][Full Text] [Related]
23. Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis. Liang J; Teng X; Yuan X; Zhang Y; Shi C; Yue T; Zhou L; Li J; Fan X Mol Immunol; 2015 Aug; 66(2):392-401. PubMed ID: 25974877 [TBL] [Abstract][Full Text] [Related]
24. Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity. Shi Z; Zhou L; Wang X; Zhang Z; Kong L; Zhang Y Arch Microbiol; 2024 Jul; 206(8):352. PubMed ID: 39012499 [TBL] [Abstract][Full Text] [Related]
25. Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis. Mani R; Gupta M; Malik A; Tandon R; Prasad R; Bhatnagar R; Banerjee N Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30104212 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins. Xiang ZH; Sun RF; Lin C; Chen FZ; Mai JT; Liu YX; Xu ZY; Zhang L; Liu J Front Cell Infect Microbiol; 2017; 7():226. PubMed ID: 28620588 [TBL] [Abstract][Full Text] [Related]
27. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940 [TBL] [Abstract][Full Text] [Related]
28. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Shi C; Chen L; Chen Z; Zhang Y; Zhou Z; Lu J; Fu R; Wang C; Fang Z; Fan X Vaccine; 2010 Jul; 28(32):5237-44. PubMed ID: 20538090 [TBL] [Abstract][Full Text] [Related]
29. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Stylianou E; Diogo GR; Pepponi I; van Dolleweerd C; Arias MA; Locht C; Rider CC; Sibley L; Cutting SM; Loxley A; Ma JK; Reljic R Eur J Immunol; 2014 Feb; 44(2):440-9. PubMed ID: 24214530 [TBL] [Abstract][Full Text] [Related]
30. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine. Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X Front Immunol; 2020; 11():575504. PubMed ID: 33117374 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein. Deng YH; He HY; Zhang FJ Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772 [TBL] [Abstract][Full Text] [Related]
32. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity. Ma J; Tian M; Fan X; Yu Q; Jing Y; Wang W; Li L; Zhou Z Oncotarget; 2016 Sep; 7(39):63804-63815. PubMed ID: 27566581 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680 [TBL] [Abstract][Full Text] [Related]
34. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772 [TBL] [Abstract][Full Text] [Related]
35. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice. Li W; Li M; Deng G; Zhao L; Liu X; Wang Y Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477 [TBL] [Abstract][Full Text] [Related]
36. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines. Grover A; Troudt J; Foster C; Basaraba R; Izzo A Immunology; 2014 May; 142(1):111-23. PubMed ID: 24350616 [TBL] [Abstract][Full Text] [Related]
37. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865 [TBL] [Abstract][Full Text] [Related]